Article
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.
Leukemia & lymphoma - 1 Feb 2009
Palandri Francesca, Ottaviani Emanuela, Salmi Federica, Catani Lucia, Polverelli Nicola, Fiacchini Mauro, Martinelli Giovanni, Baccarani Michele, Vianelli Nicola
Abstract excerpt
The JAK2(V617F) mutation occurs in 50% of patients with essential thrombocythemia (ET). We investigated the correlation between the JAK2(V617F) mutation and clinical and laboratory characteristics, thrombohemorrhagic risk and incidence of disease evolution in 275 patients with ET followed for a median follow-up of 7 years. JAK2(V617F) mutation was detected in 175 patients (64%), of whom 173 were heterozygous....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.